Table 2 Antiretroviral therapy in 81 cases and 162 controls

First line therapy

81 (100)

162 (100)

Combinations

-NRTI+PI

67 (83)

138 (85)

0.7

-NRTI+NNRTI

14 (17)

26 (16)

0.7

Duration; months (mean ± SD)

13.46 ± 10.23

16.67 ± 8.45

0.06

N° of patients who suspended

53 (66)

91 (56)

0.2

Cause of suspension

-side effects

30 (56)

37 (41)

0.1

-viro-immunological failure

8 (15)

15 (17)

0.6

Second line therapy

45 (56)

91 (56)

1

Third line therapy

11 (14)

31 (19)

0.4

Total number of drug changes (mean ± SD)

2.1 ± 0.9

2.0 ± 0.6

0.8,

Adherent to the last drug regimen

68 (84)

118 (73)

0.08

Side effects to HAART

dyslipidemia

32 (40)

55 (34)

0.5

digestive intolerance

26 (32)

58 (36)

0.6

lipodystrophy

12 (15)

23 (14)

0.7

hyperglycaemia

8 (10)

3 (2)

0.01

anaemia

8 (10)

3 (2)

0.01